Compare Citius Pharmaceuticals Inc (CTXR) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Weibo Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Weibo Corp trades at $6.51 (market cap $1.56B). The key difference: Weibo Corp is far larger — about 114.5× Citius Pharmaceuticals Inc's market cap, and Weibo Corp pays a 9.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Weibo Corp for 102 Days on average.
| CTXR | WB | |
|---|---|---|
Market Cap | $13.62M | $1.56B |
Volume | 132,438 | 812,503 |
Sector | Health | Media |
52-Week High | $1.82 | $12.37 |
52-Week Low | $0.48 | $6.33 |
Typical Hold Time | 16 Days | 102 Days |
Enterprise Value | $3.79M | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Weibo (WB) trades at $6.48, down 0.15% with bearish technical signals. The stock shows attractive valuation metrics including a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. Cash flow trends indicate volatility with a significant net outflow in 2024 followed by recovery in 2025.
Weibo presents as a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 40.9% buy ratings versus 45.5% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition in social media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
